Obermatt

Prestige Consumer Healthcare

NYQ:PBH · US74112D1019
PharmaceuticalsMedium

360

60
EV / EBIT81
Price / Owner Earnings51
Owner Earnings Yield84
Dividend Yield1
Price/Sales70
EV / Gross Profit52
Price/Book81
Return on Capital65
Cash Return on Capital57
Return on Equity55
EBIT Margin85
Gross Profitability28
Cash Conversion55
Accruals44
Owner Earnings Margin81
Sales growth61
Profit Growth78
Long-Term EPS Growth58
Owner Earnings Growth41
Reinvestment76
Price momentum10
Debt load38
Refinancing92
Debt Payback25
Liquidity67
Analyst ratings40
Opinion Changes36
Price Target Upside42
Market mood43
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Prestige Consumer Healthcare doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNYSE
Founded2004
Employees218
ISINUS74112D1019
Last UpdateApr 2, 2026
Index & Theme
OphthalmologyWomen's HealthPain ManagementDermatologyEar Nose & Throat (ENT)GastroenterologyDentistryConsumer GoodsManufacturing

Description

Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (‘OTC’) health and personal care products to mass merchandisers, drug/drug wholesale, f…

Analysis

Middle-of-the-road

Prestige Consumer Healthcare Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 10.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -2% a year, against analyst forecasts of 8%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
90
2023202420252026

All-time high

91

Feb 2024

All-time low

47

Dec 2025

Average rank

68

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
70
39
43
55
Price/Earnings
38
45
56
68
Price/Book
81
41
43
64
Dividend Yield
1
1
1
1
Value (overall)
72
36
53
49

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Prestige Consumer Healthcare with its peers
Procter & Gamble Health
NSI:PGHL
72
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Context Therapeutics
NAQ:CNTX
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
elf Beauty
NYQ:ELF
11
CountryUSA
IndustryPersonal Products
SizeMedium
Full Stock Analysis →
Abbott India
NSI:ABBOTINDIA
42
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Bausch Health Companies
TOR:BHC
21
CountryCanada
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →